Devonian Health Group Inc. (TSXV:GSD)
12.00
-0.40 (-3.23%)
At close: Mar 25, 2026
Devonian Health Group Revenue
Devonian Health Group had revenue of 487.82K CAD in the quarter ending January 31, 2026, a decrease of -94.47%. This brings the company's revenue in the last twelve months to 10.18M, down -66.65% year-over-year. In the fiscal year ending July 31, 2025, Devonian Health Group had annual revenue of 23.59M with 22.19% growth.
Revenue (ttm)
10.18M
Revenue Growth
-66.65%
P/S Ratio
3.28
Revenue / Employee
1.02M
Employees
11
Market Cap
33.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jul 31, 2025 | 23.59M | 4.28M | 22.19% |
| Jul 31, 2024 | 19.31M | 16.96M | 723.15% |
| Jul 31, 2023 | 2.35M | 40.20K | 1.74% |
| Jul 31, 2022 | 2.31M | 830.50K | 56.32% |
| Jul 31, 2021 | 1.47M | -668.47K | -31.19% |
| Jul 31, 2020 | 2.14M | -1.86M | -46.49% |
| Jul 31, 2019 | 4.00M | 837.05K | 26.42% |
| Jul 31, 2018 | 3.17M | - | - |
| Jul 31, 2017 | - | - | - |
| Jul 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionDevonian Health Group News
- 12 days ago - Devonian Reports Results of its Annual General and Special Meeting of Shareholders - PRNewsWire
- 17 days ago - Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026 - PRNewsWire
- 7 weeks ago - Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects - PRNewsWire
- 7 weeks ago - Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls - PRNewsWire
- 2 months ago - Devonian reports additional molecular data from MASH liver study - PRNewsWire
- 2 months ago - DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY - PRNewsWire
- 2 months ago - DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT - PRNewsWire
- 2 months ago - DEVONIAN ANNOUNCES SHARE CONSOLIDATION IN FURTHER PREPARATION FOR POTENTIAL U.S. LISTING - PRNewsWire